Moreover, the evaluation of CD8 E could help in detecting JCV reactivation, especially in JCV seronegative patients, who are currently considered at lower risk of developing PML during natalizumab treatment. This evidence concerns the gene CD8A and progressive multifocal leukoencephalopathy.